↑ 薬物リストへ　← 戻る

Creatinine    (DrugBank: Creatinine)

4 diseases
告示番号疾患名（ページ内リンク）臨床試験数
2筋萎縮性側索硬化症1
46悪性関節リウマチ1
60再生不良性貧血1
70広範脊柱管狭窄症1

2. 筋萎縮性側索硬化症　［臨床試験数：508，薬物数：530（DrugBank：146），標的遺伝子数：170，標的パスウェイ数：221］
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00005766
(ClinicalTrials.gov)		May 20001/6/2000Clinical Trial of Creatine in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: CreatinineNational Center for Research Resources (NCRR)NULLCompleted18 Years80 YearsBothPhase 2United States

46. 悪性関節リウマチ　［臨床試験数：4,183，薬物数：2,538（DrugBank：401），標的遺伝子数：183，標的パスウェイ数：219］
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1ChiCTR1800018637
2018-09-262018-09-30Correlation between Human epididymis protein 4 and interstitial lung disease in patients with rheumatoid arthritisCorrelation between Human epididymis protein 4 and interstitial lung disease in patients with rheumatoid arthritis rheumatoid arthritisGold Standard:Clinical outcome, meet the 2010 ACR/EULAR rheumatoid arthritis classification criteria.;Index test:Human epididymis protein 4,anti-cyclic citrullinated peptide, creatinine, rheumatoid factor;Affiliated Hospital of North Sichuan Medical CollegeNULLRecruitingBothTarget condition:150;Difficult condition:100China

60. 再生不良性貧血　［臨床試験数：218，薬物数：362（DrugBank：81），標的遺伝子数：39，標的パスウェイ数：155］
Searched query = "Aplastic anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 218 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-jRCTs071190032
26/11/201921/10/2019W-JHS AA02Investigation on the effectiveness of rabbit ATG + cyclosporine + eltrombopag therapy for patients with aplastic anemia - W-JHS AA02 aplastic anemia1. The administration of rATG; 2.5 mg/kg, iv. daily, day 1 - day 5 + CsA; 5 mg/kg, po. bid (before breakfast and before dinner) +adrenalcorticosteroid (the dose is mentioned after) is started. CsA used is Neoral or generic drug emulsified in the same way with Neoral. A blood level of CsA is measured and the dose which CsA blood level 2 hours after oral administration (C2) reachs 600 - 900 ng/mL is adjusted. The investigator shall reduce the dose of CsA by 25% on this occasion when blood trough level (C0) just before the administration is beyond 250 ng/mL because renal function disorder may occur (2). When serum creatinine level also becomes higher than 150% of baselines, the 25% dose reduction of CsA shall be performed. If C2 did not reach to 600 ng/mL, then dose of CsA is appropriately increased.
2. EPAG; 75 mg, po. daily (before sleep, requires to pass more than at least 2 hours after dinner) is started from day 6.
3. The dose of steroid is as follows:
Day 1 - day 5: methylprednisolone 2 mg/kg/day
Day 6: Methylprednisolone 1 mg/kg/day
Day 8, 10, 12, 14, 16, 18, 20: prednisolone 0.5 mg/kg/day
Discontinuation after day 21
4. The administration of CsA and EPAG is continued for 26 weeks. When it passed 26 weeks, further treatment mentioned above is entrusted to the investigator in each medical institution after 27 weeks if patients reached Camitta criteria CR or PR. However, the administration is continued for 52 weeks even if the dose of CsA is reduced. The treatment after 53 weeks is not specified. If patients did not reach CR or PR at 26 weeks, treatment after 27 weeks is entrusted to the investigator in each medical institution (it is not specified in this study).		Nakao ShinjiNULLRecruiting>= 18age old< 80age oldBoth60Phase 2Japan

70. 広範脊柱管狭窄症　［臨床試験数：91，薬物数：195（DrugBank：54），標的遺伝子数：60，標的パスウェイ数：85］
Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 91 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-jRCTs021200007
19/06/202003/06/2020MiroTASEfficacy and Safety of Mirogabalin for the Treatment as Add-On to NSAIDs in patients with Peripheral Neuropathic Pain caused by Lumbar Spinal Stenosis : Multi-institutional, randomized, open, parallel-design and interventional Study Lumber Spiral StenosisComparison in the effect and safety of Mirogabalin add-on therapy to NSAIDs and NSAIDs monotherapy for patients with Lumber Spiral Stenosis and administrated of NSAIDs.
1) NSAIDs monotherapy as a study drug are prescribed in accordance with a package insert and each of their administration and dosage is not changed while a study drug is administrated.
2) Mirogabalin add-on therapy to NSAIDs: NSAIDS as a study drug are prescribed in accordance with a package insert and each of their administration and dosage is not changed while a study drug is administrated. Mirogabalin is prescribed as follows in accordance with renal function of a subject.
Patients with creatinine clearance more than 60mL/min: Mirogabalin is administrated in dose of 5mg twice a day at the first week. At the next week, Mirogabalin is administrated in dose of 10mg twice a day. At week 5(after Visit3), dose of Milogabalin is increased to 15mg twice a day unless there is no problem with the safety. After that, the dose of Mirogabalin is controlled by 10mg twice a day or 15mg twice a day depending on safety findings.
Patients with creatinine clearance 30-60mL/min: Mirogabalin is administrated in dose of 2.5mg twice a day at the first week. At the next week, Mirogabalin is administrated in dose of 5mg twice a day. At week 5(after Visit3), dose of Milogabalin is increased to 7.5mg twice a day unless there is no problem with the safety. After that, the dose of Mirogabalin is controlled by 5mg twice a day or 7.5mg twice a day depending on safety findings.
Also, more than 7 days washout period before enrollment is required for target patients administrated of prohibited drugs.
If the administration of Mirogabalin is discontinued, down-titration is needed in accordance with the insert package.		Nikaido TakuyaDaiichi Sankyo Co., LtdRecruiting>= 20age oldNot applicableBoth300N/AJapan